Subjective and functional deterioration in recurrences of neovascular AMD are often preceded by morphologic changes in optic coherence tomography

British Journal of Ophthalmology

Volumn 95, Issue 10, 2011, Pages 1424-1426

  Hoerster, Robert ^a   Muether, Philipp S ^a   Hermann, Manuel M ^a   Koch, Konrad ^a   Kirchhof, Bernd ^a   Fauser, Sascha ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

AGED; AMSLER GRID TEST; ARTICLE; B SCAN; CASE STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DIABETIC RETINOPATHY; EXUDATIVE MACULAR DEGENERATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; METAMORPHOSIS; MORPHOLOGY; OPHTHALMOSCOPY; PERCEPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; RETINA MACULA AGE RELATED DEGENERATION; SCOTOMA; SELF CONTROL; SENSITIVITY ANALYSIS; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CONTRAST SENSITIVITY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; PROSPECTIVE STUDIES; RECURRENCE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 80053271504     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2010.201129     Document Type: Article

References (18)

1. Augood C, Fletcher A, Bentham G, et al. Methods for a population-based study of the prevalence of and risk factors for age-related maculopathy and macular degeneration in elderly European populations: the EUREYE study. Ophthalmic Epidemiol 2004;11:117-29. (Pubitemid 38530466)
2. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004;291:1900-1. (Pubitemid 38509505)
3. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-2. (Pubitemid 15204559)
4. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72. (Pubitemid 38456293)
5. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844-51. (Pubitemid 39573742)
6. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44. (Pubitemid 44511558)
7. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. (Pubitemid 44511557)
8. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
9. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intra-vitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83.
10. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58 e41.
11. Meyer CH, Eter N, Holz FG. Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Interim results from the Sustain Trial [abstract]. Invest Ophthalmol Vis Sci 2008;49:E-abstract 273.
12. Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 2008;145:249-56.
13. Bashshur ZF, Haddad ZA, Schakal AR, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol 2009;148:59-65 e51.
14. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-48.
15. Parravano M, Oddone F, Tedeschi M, et al. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab: 24-month results. Retina 2009;30:1017-24.
16. Squirrell DM, Mawer NP, Mody CH, et al. Visual outcome after intravitreal ranibizumab for wet age-related macular degeneration: a comparison between best-corrected visual acuity and microperimetry. Retina 2010;30:436-42.
17. Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010;117:2134-40.
18. Muether PS, Hermann MM, Koch K, et al. Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity. Graefes Arch Clin Exp Ophthalmol 2011;249:633-7.